Form 4: Director Howard Clowes Acquires Stock Options in Plus Therapeutics
SEC Form 4 Filing
Howard Clowes, a director of Plus Therapeutics, acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.
Summary
- On September 11, 2024, Howard Clowes, a director of Plus Therapeutics, acquired stock options to purchase 3,650 shares of the company's common stock.
- The exercise price of these options is $1.26 per share.
- The options vest monthly over 12 months from the grant date, or in full at the next annual meeting of stockholders, subject to continued service.
- The options expire on September 11, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by potentially diluting the stock if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of the transaction: Howard Clowes acquired stock options. |
| 09/12/2024 | Date of signature on the Form 4 filing. |
| 09/11/2034 | Expiration date of the stock options. |
Keywords
stock options, Form 4, beneficial ownership, Plus Therapeutics, director, Howard Clowes, PSTV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.